Illumina Inc. announced the launch of TruPath Genome, a whole-genome sequencing workflow for genetic disease research. The company said TruPath Genome eliminates traditional library preparation and requires about 10 minutes of hands-on time, producing up to 16 whole genomes per day. Illumina reported that TruPath Genome fully phases up to 98% of genes and is priced at a $395 USD list price per genome, including consumables and analysis at at least 30x coverage using a single-use flow cell. Illumina also said more than 30 early access customers piloted the technology over the past 16 months, and Broad Clinical Labs is among the first adopters.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602241215PR_NEWS_USPR_____LA94213) on February 24, 2026, and is solely responsible for the information contained therein.